Imaging D2 receptor occupancy by endogenous dopamine in humans

Neuropsychopharmacology

Volumn 17, Issue 3, 1997, Pages 162-174

  Laruelle, Marc ^a,b   D'Souza, Cyril D ^a   Baldwin, Ronald M ^a   Abi Dargham, Anissa ^a   Kanes, Stephen J ^a   Fingado, Christine L ^a   Seibyl, John P ^a   Zoghbi, Sami S ^a   Bowers, Malcolm B ^a   Jatlow, Peter ^a   Charney, Dennis S ^a   Innis, Robert B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The New York Presbyterian Hospital   (United States)

Author keywords

AMPT; Dopamine; Dopamine D2 receptors; Human; In vivo binding; Schizophrenia; Striatum; 123I IBZM

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; METIROSINE; TRACER; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; ENZYME INHIBITOR; HOMOVANILLIC ACID; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ARTICLE; CORPUS STRIATUM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AFFECT; ANIMAL; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PARKINSON DISEASE; RAT; SPRAGUE DAWLEY RAT;

ADULT; AFFECT; ALPHA-METHYLTYROSINE; ANIMALS; BENZAMIDES; BRAIN; DOPAMINE; ENZYME INHIBITORS; HOMOVANILLIC ACID; HUMANS; IODINE RADIOISOTOPES; MALE; METHOXYHYDROXYPHENYLGLYCOL; PARKINSON DISEASE, SECONDARY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TYROSINE 3-MONOOXYGENASE;

EID: 0030608782     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00043-2     Document Type: Article

References (51)

1. Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter S (1995): Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schiz Bull 21:53-66
2. Anderson GM, Young GJ, Cohen DJ, Schlicht KR, Patel N (1981): Liquid-chromatographic determination of serotonin and tryptophan in whole blood and plasma. Clin Chem 27:775-776
3. Bacopoulos N, Henninger G, Roth R (1978): Effects of haloperidol and probenecid on plasma and CSF dopamine metabolites in the rhesus monkey (Macacca mulatta). Life Sci 23:1805-1812
4. Brodie HK, Murphy DL, Goodwin FK, Bunney W Jr (1971): Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 12:218-224
5. 125I] IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 42:2097-2104
6. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42
7. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356
8. Engelman K, Jequier E, Udenfriend S, Sjoerdsman A (1968): Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. J Clin Invest 47:568-576
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
10. Farde L, Wiesel FA, Nordström AL, Sedvall G (1989): D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptic. Psychopharmacology 99:S28-S31
11. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB (1994): Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 83:1014-1019
12. 3H]raclopride to rat and human brain membranes. J Neurochem 55:2048-2057
13. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995): Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36:1275-1281
14. Hamblin MW, Lef SF, Creese I (1984): Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Bioch Pharmacol 33:877-887
15. Hornykiewicz O, Kish SJ (1987): Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
16. 2 receptor in non-human primates. Synapse 10:177-184
17. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM (1992): Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51:55-64
18. D with the opiate antagonist cyclofoxy: equilibrium studies in the conscious rat. J Cereb Blood Flow Metab 11:529-544
19. 2 receptors. Synapse 15:169-176
20. 123I]IBZM, a potential dopamine D-2 receptor imaging agent. J Lab Comp Radiopharm 27:691-700
21. Lang AE, Marsden CD (1982): Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 5:375-387
22. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453-465
23. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996a): Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci 93:9235-9240
24. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB (1995): SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190
25. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997): Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
26. 3H]raclopride. Proc Natl Acad Sci 86:6412-6416
27. 18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9:195-207
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951): Protein measurement with folin phenol reagent. J Biol Chem 193:263-274
29. Maas JW, Hattox SE, Landis DH (1976): The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenethyleneglycol (MHPG). Brain Res 118: 167-173
30. Mignot E, Laude D (1985): Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine. J Neurochem 45: 1527-1533
31. Munson P, Rodbard D (1980): LIGAND: A versatile computerized approach for characterization of ligand binding systems. Ann Biochem 107:220-239
32. 2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. J Chem Neuroanatomy 9:41-53
33. Richfield EK, Young AB, Penney JB (1986): Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383:121-128
34. Ross SB (1991): Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56:22-29
35. Ross SB, Jackson DM (1989a): Kinetic properties of the in vivo accumulation of the dopamine D-2 receptor antagonist raclopride in the mouse brain in vivo. Naunyn Schmiedeberg Arch Pharmacol 340:6-12
36. 3H](-)-N-n-propylnorapomorphine in the mouse brain. Naunyn Schmiedeberg Arch Pharmacol 340:13-20
37. Seeman P (1993): Receptor Tables. Vol. 2: Drug Dissociation Constants for Neuroreceptors and Transporters. Toronto, Canada
38. Seeman P, Niznik HB, Guan H-C (1990): Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry 47:1170-1172
39. 2 receptors in human subjects with iodine-123-IBZM. J Nucl Med 33:1964-1971
40. Sibley DR, Creese I (1980): Pseudo non-competitive interactions with dopamine receptors. Eur J Pharmacol 65:131-133
41. 2 dopamine receptor. J Biol Chem 257:6351-6361
42. Simpson GM, Angus JWS (1970): A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:1-58
43. Spector S, Sjoerdsma A, Udenfriend S (1965): Blockade of endogenous norepinephrine synthesis by alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther 147:86-95
44. Udenfriend S, Nagatsu T, Zaltzman-Nirenberg P (1965): Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14:837-847
45. USP XXIII (1995): Sterility test. In: (eds), The United States Pharmacopeia. Rockville, MD, United States Pharmacopeial Convention, Inc., pp 1686-1690
46. Van der Werf JF, Sebens JB, Vaalburg W, Korf J (1986): In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol 87:259-270
47. 11C]raclopride in the human brain. Synapse 16:255-262
48. Watanabe M, George SR, Seeman P (1985): Dependence of dopamine receptor conversion from agonist high to low-affinity state on temperature and sodium ions. Biochem Pharmacol 34:2459-2463
49. 3H]raclopride binding in the rat brain. Synapse 9:188-194
50. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI (1995): Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730
51. 123I]iomazenil in human and nonhuman primates. Nucl Med Biol 19:5